AVXL Stock — Anavex Life Sciences Corp.: Cash, EV, Pipeline

Share price

$2.42

Market cap

$224.3M

Cash

$118.3M

Enterprise value

$106.0M

Balance sheet

Cash	$118.3M
Debt	$0.0M
Net cash	$118.3M
Enterprise value	$106.0M
Basic shares	92.7M shares
Fully diluted shares	115.7M shares
Fully diluted market cap	$280.0M
Cash per share	$1.28

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AVXL daily closes…

Loading price history…

Pipeline assets

ANAVEX 2-73 (blarcamesine)

Phase 3 · Active Modality: Small molecule

Target Sigma-1 receptor (SIGMAR1)

Indications

Early Alzheimer's disease (MCI due to AD + mild AD) (Phase 3)
Rett syndrome (Phase 3)
Fragile X syndrome (Stage not disclosed)

Catalysts

— 2026 (September)

Status note Lead compound. EMA MAA for Alzheimer's withdrawn Mar 2026 (CHMP negative benefit-risk); initiating Phase 3 Rett syndrome study. Seeking FDA alignment on early-AD Phase 3 and Fragile X strategy; nonclinical/ADME/DDI studies underway under AD IND.

ANAVEX 3-71

Phase 1 · Active Modality: Small molecule (oral)

Target Sigma-1 receptor (SIGMAR1) / M1 muscarinic

Partnerships Life Science Research Israel Ltd (LSRI): exclusive IP license (regulatory milestone payments + royalties)

Indications

Frontotemporal dementia (Orphan Drug Designation) (Stage not disclosed)

Status note Clinical-stage; development paused under new leadership pending funding or strategic partnership.

ANAVEX 1-41

Preclinical · Active Modality: Small molecule

Target Sigma-1 receptor (SIGMAR1) / M1 muscarinic

Indications

not disclosed (Preclinical)

Status note De-prioritized; development paused and contingent on additional funding or a strategic partnership (license/sale possible).

ANAVEX 1066

Preclinical · Active Modality: Small molecule

Target Sigma-1 / sigma-2

Indications

Neuropathic and visceral pain (Preclinical)

Status note De-prioritized; development paused and contingent on additional funding or a strategic partnership (license/sale possible).

Per-asset detail extracted from the 10-Q filed 2026-08-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ANAVEX3-71 oral capsules
Lead indication	Schizophrenia
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06245213	Phase 2	Active, not recruiting	Sponsor	AVXL	—	Schizophrenia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Anavex Life Sciences Corp. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AVXL — Anavex Life Sciences Corp.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials